KVA-12123 is a monoclonal antibody commercialized by Kineta, with a leading Phase II program in Transitional Cell Cancer (Urothelial Cell Cancer). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of KVA-12123’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData


Data Insights Net Present Value Model: Kineta Inc's KVA-12123

Buy the Model

Data Insights

The gold standard of business intelligence.

Find out more

The revenue for KVA-12123 is expected to reach an annual total of $239 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

KVA-12123 Overview

KVA-12123 is under development for the treatment of solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), ovarian cancer (OC), renal cell carcinoma, melanoma and head and neck cancer squamous cell carcinoma, bladder cancer, leiomyosarcoma, colon cancer, transitional cell cancer (urothelial cell cancer), pancreatic cancer. It acts by targeting v-region immunoglobulin-containing suppressor of T cell activation (VISTA). It is administered through intravenous route as infusion. It was also under development for acute myelocytic leukemia (AML). It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. It was under development for the treatment of hepatocellular carcinomas, squamous cell carcinoma of the skin and cervical cancer.

Kineta Overview

Kineta, formerly Yumanity Therapeutics Inc, is a clinical stage development company focused on the development of next-generation immunotherapies. Kineta has successfully established its Innate Immunity Development Platform with the purpose of creating fully human antibodies that target the key mechanisms responsible for cancer immune resistance. These mechanisms include immuno-suppression, exhausted T cells, and poor tumor immunogenicity. Its major pipeline products include KVA12123, Anti-CD27 agonist mAb immunotherapy and Anti-CD24 antagonistmAb immunotherapy. Kineta is headquartered in Seattle, Washington, the US.
The company reported revenues of (US Dollars) US$2 million for the fiscal year ended December 2022 (FY2022), a decrease of 75.7% over FY2021. The operating loss of the company was US$41.2 million in FY2022, compared to an operating loss of US$37.6 million in FY2021. The net loss of the company was US$63.4 million in FY2022, compared to a net loss of US$39.5 million in FY2021.

For a complete picture of KVA-12123’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.